Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 154

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 154
---
 for performing
regulatory submissions, marketing and distribution directly to clinicians.

We remain focused on performing
investigational studies to evaluate the potential efficacy of the Alpha DaRT as a monotherapy and an immuno-stimulating combination therapy,
and on supplementing our robust patent portfolio across a broad range of tumor applications, as we continue to navigate the regulatory
pathways towards commercialization. We believe that these studies will also allow us to better explore the question of which clinicians
are ultimately our end customer for commercial purposes, given the involvement of multiple practitioners including the radiation oncologist,
medical physicist, and the clinician delivering the Alpha DaRT such as the oncology surgeon or interventional radiologist.

Competition

The biotechnology, medical
device and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense
competition and a strong emphasis on intellectual property. We face potential competition from many different sources, including major
pharmaceutical, medical device, specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies
and public and private research institutions.

In the field of local therapy
for solid tumors, we face competition from new or continually improving surgical techniques, as well as a number of radiation therapies
- EBRT, stereotactic body radiation therapy, intensity-modulated radiation therapy, brachytherapy, and others, as well as particle therapies
such as proton therapy, neutron therapy and carbon ion therapy. There are several companies developing improved or new forms of local
radiation therapy, including Varian Medical Systems, Inc. (a subsidiary of Siemens Healthineers), Elekta AB, BTG plc (a subsidiary of
Boston Scientific Corporation), ViewRay, Inc., Accuray, Inc., RefleXion Medical, Inc.

In addition, in the field
of systemic therapy for cancer, commercial and academic clinical trials are being pursued by a number of parties in the field of radiopharmaceuticals,
some of which involve the use of alpha radiation as well. Early results from these trials have fueled continued interest in radiopharmaceuticals,
which is being pursued by several biotechnology companies as well as by large pharmaceutical companies.

There are several companies
developing targeted alpha-based radiopharmaceuticals for the treatment of cancer, including Bayer AG, or Bayer, Novartis AG, Fusion Pharmaceuticals
Inc. (which has been acquired by AstraZeneca plc), RayzeBio, Inc. (which has been acquired by Bristol-Myers Squib